

PG4894USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Weingarten et al.

Serial No.: 10/524,462

Group Art Unit: 1615

File Date: October 18, 2005

Examiner:

For: Pyrimidine Derivatives As Selective COX-2 Inhibitors

Director of the U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed: References 8-46

☐ Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

  
J. Scott Young  
Registration No. 45,582

Date: Aug 3 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8160  
Facsimile: (919) 483-7988

**FORM PTO-1449**  
**INFORMATION DISCLOSURE STATEMENT**

<b>SERIAL NO.</b>	10/527,799
<b>FILING DATE</b>	August 17, 2005
<b>APPLICANT</b>	Beswick et al.
<b>GROUP</b>	1614
<b>EXAMINER</b>	
<b>ATTORNEY DOCKET NO.</b>	PG4893USW

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	2003/0018023	Jan. 23, 2003	Pinto et al.			
	2	5,849,758	Dec. 15, 1998	Kleemann et al.			
	3	5,972,842	Oct. 26, 1999	Maier et al.			
	4	5,985,886	Nov. 16, 1999	Elliott et al.			
	5	6,121,202	Sept. 19, 2000	Karp et al.			
	6	6,248,892	June 19, 2001	Noerenborg et al.			
	7	6,355,799	Mar. 12, 2002	Gupta et al.			

Continue on page

**FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes / No
	8	DE 19651099	June 10, 1998	GERMANY			X Abstract
	9	DE 19708928	Sept. 10, 1998	GERMANY			X Abstract
	10	DE 19831246	Jan. 1, 2000	GERMANY			X Abstract
	11	EP 0723960	July 31, 1996	EUROPE			
	12	EP 0820996	Jan. 28, 1998	EUROPE			
	13	JP 2000026421	Jan. 25, 2000	JAPAN			X Abstract
	14	JP 2001081074	Mar. 27, 2001	JAPAN			X Abstract
	15	JP 2001252044	Nov. 22, 1999	JAPAN			X Abstract
	16	WO 97/38996	Oct. 23, 1997	WIPO			
	17	WO 99/21837	May 6, 1999	WIPO			
	18	WO 99/55668	April 11, 1999	WIPO			X Abstract
	19	WO 99/12930	Mar. 18, 1999	WIPO			
	20	WO 00/26216	May 11, 2000	WIPO			
	21	WO 00/47553	Aug. 17, 2000	WIPO			
	22	WO 00/52008	Sept. 8, 2000	WIPO			
	23	WO 01/45703	June 28, 2001	WIPO			
	24	WO 01/46194	June 8, 2001	WIPO			
	25	WO 01/41760	June 14, 2001	WIPO			
	26	WO 01/56573	Aug. 9, 2001	WIPO			
	27	WO 01/62233	Aug. 30, 2001	WIPO			
	28	WO 01/83479	Nov. 8, 2001	WIPO			
	29	WO 02/00647	Jan. 3, 2002	WIPO			
	30	WO 02/00655	Jan. 3, 2002	WIPO			
	31	WO 02/44137	June 6, 2002	WIPO			
	32	WO 02/55484	July 18, 2002	WIPO			X Abstract
	33	WO 02/59122	Aug. 1, 2002	WIPO			X Abstract
	34	WO 02/96427	Dec. 5, 2002	WIPO			

Continue on page 2

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

35	Stichtenoth, D.O., et al. "The Second Generation of COX-2 Inhibitors." <i>Drugs</i> , 63(1), 2003, pgs. 33-45.
36	FDA Label for Celebrex, 20-998, June 29, 2005.
37	FDA Label for Vioxx, 21-042, May 20, 1999.

Continue on page

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

